Lingfang Xia

No. 270, Dong'an Road, 20032
Xuhui, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.

Journal: BMJ open

Published: April 16, 2026

Ultrasmall nanosonocatalyst induces PANoptosis to suppress ovarian cancer: From patient-derived organoids to in vivo models.

Ultrasmall nanosonocatalyst induces PANoptosis to suppress ovarian cancer: From patient-derived organoids to in vivo models.

Journal: Biomaterials

Published: April 08, 2026

Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.

Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.

Journal: Genome medicine

Published: June 26, 2025

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2025

m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.

m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.

Journal: Oncogene

Published: September 01, 2024

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report.

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report.

Journal: Journal of ovarian research

Published: August 07, 2024

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 24, 2023

PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.

PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.

Journal: Oncogene

Published: July 06, 2023

The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.

The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.

Journal: Cancer letters

Published: February 19, 2023

TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.

TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.

Journal: Molecular carcinogenesis

Published: December 21, 2022

Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.

Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.

Journal: Acta obstetricia et gynecologica Scandinavica

Published: November 16, 2022

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.

Journal: Nature communications

Published: June 24, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026